M Hinchcliffe
Overview
Explore the profile of M Hinchcliffe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
418
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Klas S, Petrie C, Warwood S, Williams M, Olds C, Stenz J, et al.
Vaccine
. 2008 Aug;
26(43):5494-502.
PMID: 18703110
Here we confirm that intranasal (IN) dry powder anthrax vaccine formulations are able to protect rabbits against aerosol challenge 9 weeks after a single immunization. The optimum dose of rPA...
2.
Wimer-Mackin S, Hinchcliffe M, Petrie C, Warwood S, Tino W, Williams M, et al.
Vaccine
. 2006 Mar;
24(18):3953-63.
PMID: 16530302
An intranasal vaccine targeting the Bacillus anthracis toxin and vegetative bacterium was tested for the ability to protect immunized rabbits against aerosol B. anthracis spore exposure. Rabbits were vaccinated intranasally...
3.
Illum L, Hinchcliffe M, Davis S
Pharm Res
. 2003 Oct;
20(9):1474-84.
PMID: 14567644
Purpose: Investigate the effect of blood sampling site and physicochemical characteristics of drugs on the pharmacokinetic (PK) parameters obtained after intravenous and nasal administration in sheep and compare results with...
4.
Dyer A, Hinchcliffe M, Watts P, Castile J, Jabbal-Gill I, Nankervis R, et al.
Pharm Res
. 2002 Aug;
19(7):998-1008.
PMID: 12180553
Purpose: To investigate whether the widely accepted advantages as sociated with the use of chitosan as a nasal drug delivery system might be further improved by application of chitosan formulated...
5.
Illum L, Watts P, Fisher A, Hinchcliffe M, Norbury H, Jabbal-Gill I, et al.
J Pharmacol Exp Ther
. 2002 Mar;
301(1):391-400.
PMID: 11907197
Morphine administered nasally to humans as a simple solution is only absorbed to a limited degree, with a bioavailability of the order of 10% compared with intravenous administration. This article...
6.
Cheng Y, Watts P, Hinchcliffe M, Hotchkiss R, Nankervis R, Faraj N, et al.
J Control Release
. 2002 Feb;
79(1-3):243-54.
PMID: 11853935
A novel nasal formulation, in the form of a nicotine-Amberlite resin complex powder has been developed that provided an optimal combined pulsatile and sustained plasma nicotine profile for smoking cessation....
7.
Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher A, Davis S
Adv Drug Deliv Rev
. 2001 Aug;
51(1-3):81-96.
PMID: 11516781
A variety of different types of nasal vaccine systems has been described to include cholera toxin, microspheres, nanoparticles, liposomes, attenuated virus and cells and outer membrane proteins (proteosomes). The present...
8.
Soane R, Hinchcliffe M, Davis S, Illum L
Int J Pharm
. 2001 Apr;
217(1-2):183-91.
PMID: 11292554
This paper describes the clearance characteristics of two bioadhesive nasal delivery systems in the form of chitosan microspheres and chitosan solution, from the nasal cavity of conscious sheep. The pattern...
9.
Davis S, Illum L, Hinchcliffe M
J Pharm Pharmacol
. 2001 Feb;
53(1):33-9.
PMID: 11206190
The gastrointestinal transit of liquid, pellet and tablet formulations was measured under fasted conditions in the domestic pig (n = 4) using the technique of gamma scintigraphy. The mean times...
10.
Bacon A, Makin J, Sizer P, Jabbal-Gill I, Hinchcliffe M, Illum L, et al.
Infect Immun
. 2000 Sep;
68(10):5764-70.
PMID: 10992483
We have evaluated the ability of two carbohydrate biopolymers, chitosan and gellan, to enhance antibody responses to subunit influenza virus vaccines delivered to the respiratory tracts of mice. Groups of...